Navigation Links
Studies show everolimus-eluting stent implantation reduces restenosis and repeat revasculariztion
Date:10/21/2010

Two new studies have determined that everolimus-eluting stent (EES) implantation reduced the incidence of restenosis and repeat revascularization in patients with calcified culprit lesions, and had fewer clinical events. Results show the rate of major cardiac adverse events in EES-treated patients with calcified lesions were higher than in those for noncalcified lesions, but remained lower than the results of previously reported stent studies. Details of both studies are published in the November issue of Catheterization and Cardiovascular Intervention, a peer-reviewed journal from The Society for Cardiovascular Angiography and Interventions.

The treatment of calcified coronary stenosis is associated with a high frequency of restenosis and target lesion revascularization (TLR). Drug-eluting stents (DES), known to reduce the rates of restenosis and TLR in patients with relatively simple coronary artery lesions when compared with bare metal stents (BMS), are now successfully being used for more advanced lesions such as calcified coronary stenoses.

The XIENCE V EES emerged in 2008 as a new option in DES. Following favorable results with this device in the SPIRIT FIRST randomized study, the SPIRIT II and III trials were performed to evaluate the EES in comparison with the widely used TAXUS paclitaxel-eluting stent (PES) in the treatment of patients with coronary artery disease. The SPIRIT studies suggested positive outcomes for EES implantation in calcified culprit lesions, with the aim of the current analysis to confirm its safety and efficacy in patients with calcified and noncalcified culprit lesions.

In the first study, researchers from the Erasmus Medical Center in the Netherlands identified 212 patients with 247 lesions, who were treated with EES alone. Target lesions were angiographically classified as none/mild, moderate, or severe grades of calcification. The population was divided into two groups: those with at least one target lesion moderately or severely calcified (the calcified group: 68 patients with 75 calcified lesions) and those with all target lesions having mild or no calcification (the noncalcified group: 144 patients). Six-month and 2-year angiographic follow-up and clinical follow-up to 3 years were completed.

At the 6-month and 2-year follow-ups, the calcified group (compared with the noncalcified group) had significantly higher rates of in-stent angiographic binary restenosis (ABR) and ischemia-driven (ID) TLR, resulting in numerically higher major cardiac adverse events (MACE). While at 3 years, only ID-TLR tended to be higher in the calcified group than in the noncalcified group, resulting in numerically higher MACE.

"The geometry and rigidity of calcified culprit lesions often prevent optimal device delivery, deployment, and conformability," explained study leader Patrick Serruys, M.D., Ph.D. "Consequently, the treatment of this lesion subset with percutaneous coronary intervention (PCI) is associated with a high frequency of acute complications and a low-success rate. Our study showed high-clinical device success (98.7%), excellent clinical procedural success (100%), and the absence of MACE during the acute phase (up to 30 days after stent implantation) in the calcified group."

Additionally, no patient in the calcified group suffered from stent thrombosis up to 3 years after PCI, while two thrombotic complications occurred in the noncalcified group. Although large population studies with long-term follow-up are mandatory, the authors concluded that EES implantation for calcified culprit lesions appears to be safe up to 3 years. This study also demonstrated that the rates of in-stent ABR (4.3%) and ID-TLR (5.9%) at 6 months for calcified culprit lesions are remarkably lower than that in previous BMS studies, in which these rates ranged from 12 to 23% and from 18 to 23%, respectively, suggesting that EES implantation is more effective for calcified culprit lesions than BMS implantation.

In a related study, researchers from the Wake Forrest University School of Medicine in North Carolina analyzed data from SPIRIT III clinical trial to evaluate whether EES, with thinner stent struts and polymer, results in less adverse outcomes. Findings from the SPIRIT III trial indicated that the newer generation of DES, the EES, was associated with fewer clinical events than the first generation PES. In an effort to determine whether this benefit extended to all patient subgroups, Robert Applegate, MD, FSCAI, and colleagues assessed the impact of jailed side branches on clinical outcomes and periprocedural myonecrosis within each stent treatment group.

The Wake Forest researchers identified 113 patients in the EES group and 63 patients in the PES group who met the criteria of having a lesion with a jailed side branch (less than 2 mm diameter, and less than 50% stenosis). Two-year clinical outcomes were evaluated, revealing that MACE (cardiac death, myocardial infarctions (MI), or TLR) occurred in 6.8% of EES and 19.0% of PES jailed side branch patients, with numerically lower rates of MI and TLR in the EES group, with comparable rates of cardiac death.

Use of a PES was associated with an increase in rates of periprocedural creatine kinase-MB fraction (CK-MB) elevation, which was most prevalent in those patients with a jailed side branch. In contrast, rates of CK-MB elevation were similar in those patients receiving an EES, and lower when compared to PES, regardless of the presence or absence of a jailed side branch. The clinical outcomes at 1 and 2 years were similar in the EES treated patients with and without a jailed side branch, but were numerically higher in the PES treated patients with a jailed side branch compared to those without a jailed side branch.

Dr. Applegate concluded, "Our observations confirm previous studies demonstrating a relative increase in the incidence of periprocedural elevation of biomarkers with PES use, and demonstrate the absence of this phenomenon with EES."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. UC studies show marijuana has therapeutic value, reports to legislature
2. Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies
3. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
4. COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology
5. Promega - TOP srl Agreement Enables Live Animal Imaging for Cancer Studies
6. Most Drug Studies Dont Help Docs Pick Best Treatment
7. Gays, Lesbians Excluded From Some Medical Studies
8. Studies Show Significant Increases of C. Difficile Infections (CDI)
9. Studies examine Third Eye Retroscope during colonoscopy
10. Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation
11. New studies on surgical options in inherited breast cancer show drastic treatment is not always best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... 2016 , ... Mental health watchdog Citizens Commission on Human Rights (CCHR) ... of psychiatry Thomas Szasz, is continuing its protest against the use of electroshock (ECT) ... Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent protest at the annual ...
(Date:5/24/2016)... ... 24, 2016 , ... Boyd Industries, a leading supplier of dental chairs ... product for pediatric dentistry , at AAPD 2016, the annual conference and trade ... The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking pieces of the ...
(Date:5/24/2016)... San Mateo, CA (PRWEB) , ... May 24, ... ... society dedicated to advancing the science and clinical practice of radiosurgery, is recognizing ... fields of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, ... first penis transplant in the United States . The 64-year-old patient who received the ... The transplant could restore not only a natural appearance, but also urinary and sexual ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, the consumer ... will deliver a new series of Q&A videos to clinicians and patients at ... expertise of Harvard Medical School faculty into brief videos that clinicians using vidscrip ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Cellvizio Highlighted in Physician ... Meeting and 91 st Congress of the ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... that its Cellvizio platform is being highlighted at ... the month of May. The first meeting highlighting ...
(Date:5/19/2016)... According to a new market research report ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is ... of 13.9% from 2016 to 2021.      (Logo: ... Tables spread through 26 Pages and in-depth TOC on ...
Breaking Medicine Technology: